MP
KYTX icon

Mangrove Partners’s Kyverna Therapeutics KYTX Stock Holding History

Mangrove Partners’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-27,014
Closed -$233K – 603
2026
Q1 		$233K Buy
+27,014
New +$225K 0.02% 307

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

Mangrove Partners's KYTX Position: Q2 2026 in Review

Mangrove Partners sold out of Kyverna Therapeutics (KYTX) in Q2 2026, closing a stake of 27,014 shares — an estimated $233K sold.

Mangrove Partners first reported a position in KYTX in Q1 2026 and held it in 1 quarter. The position peaked at $233K in Q1 2026. 120 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • Mangrove Partners reported no remaining Kyverna Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Mangrove Partners sold 27,014 Kyverna Therapeutics shares in Q2 2026, an estimated $233K.
  • Mangrove Partners first reported a position in Kyverna Therapeutics in Q1 2026 and held it in 1 quarter.
  • Mangrove Partners's Kyverna Therapeutics position peaked at $233K in Q1 2026.
  • 120 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Mangrove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.